Korea Investment CORP bought a new position in Repligen Co. (NASDAQ:RGEN – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,022 shares of the biotechnology company’s stock, valued at approximately $2,882,000.
Other large investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans lifted its holdings in Repligen by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 177,458 shares of the biotechnology company’s stock worth $30,046,000 after acquiring an additional 2,491 shares during the last quarter. Credit Suisse AG raised its holdings in shares of Repligen by 1.5% during the third quarter. Credit Suisse AG now owns 52,577 shares of the biotechnology company’s stock valued at $9,837,000 after buying an additional 758 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Repligen by 3.6% during the third quarter. Amalgamated Bank now owns 39,981 shares of the biotechnology company’s stock valued at $7,481,000 after buying an additional 1,395 shares during the last quarter. Congress Wealth Management LLC DE raised its holdings in shares of Repligen by 20.2% during the third quarter. Congress Wealth Management LLC DE now owns 7,042 shares of the biotechnology company’s stock valued at $1,318,000 after buying an additional 1,185 shares during the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Repligen by 14.8% during the third quarter. MML Investors Services LLC now owns 11,061 shares of the biotechnology company’s stock valued at $2,070,000 after buying an additional 1,429 shares during the last quarter. Institutional investors own 91.00% of the company’s stock.
Repligen Stock Performance
NASDAQ RGEN opened at $167.26 on Monday. The stock has a market capitalization of $9.31 billion, a P/E ratio of 56.70, a P/E/G ratio of 2.95 and a beta of 1.07. Repligen Co. has a 1 year low of $137.65 and a 1 year high of $262.26. The business’s fifty day moving average is $163.24 and its two-hundred day moving average is $171.90.
Insider Buying and Selling at Repligen
In other news, Director Martin D. Madaus bought 500 shares of the business’s stock in a transaction on Monday, May 8th. The shares were bought at an average cost of $156.18 per share, with a total value of $78,090.00. Following the purchase, the director now directly owns 1,611 shares in the company, valued at $251,605.98. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.10% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. Benchmark cut their price target on Repligen from $230.00 to $210.00 in a report on Wednesday, May 3rd. TheStreet cut Repligen from a “b-” rating to a “c+” rating in a report on Monday, May 8th. StockNews.com began coverage on Repligen in a report on Thursday, May 18th. They set a “sell” rating on the stock. Stifel Nicolaus dropped their target price on Repligen from $225.00 to $210.00 in a report on Wednesday, May 3rd. Finally, KeyCorp dropped their target price on Repligen from $260.00 to $240.00 and set an “overweight” rating on the stock in a report on Thursday, February 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $208.56.
Repligen Profile
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.
Featured Articles
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- Will Nvidia Be the Lifeline Intel Desperately Needs?
- Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
